{"pmid":32329920,"title":"The care of patients with Duchenne, Becker and other muscular dystrophies in the COVID-19 pandemic.","text":["The care of patients with Duchenne, Becker and other muscular dystrophies in the COVID-19 pandemic.","The corona virus disease 2019 (COVID-19) pandemic has resulted in the reorganization of healthcare settings affecting clinical care delivery to patients with Duchenne and Becker muscular dystrophy (DBMD) as well as other inherited muscular dystrophies. The magnitude of the impact of this public health emergency on the care of patients with DBMD is unclear as they are suspected of having an increased risk for severe manifestations of COVID-19. In this paper, the authors discuss their consensus recommendations pertaining to care of these patients during the pandemic. We address issues surrounding corticosteroid and exon skipping treatments, cardiac medications, hydroxychloroquine use, emergency/respiratory care, rehabilitation management, and the conduct of clinical trials. We highlight the importance of collaborative treatment decisions between the patient, family, and health care provider, considering any geographic or institution-specific policies and precautions for COVID-19. We advocate for continuing multidisciplinary care for these patients using telehealth. This article is protected by copyright. All rights reserved.","Muscle Nerve","Veerapandiyan, Aravindhan","Wagner, Kathryn R","Apkon, Susan","McDonald, Craig M","Mathews, Katherine D","Parsons, Julie A","Wong, Brenda L","Eichinger, Katy","Shieh, Perry B","Butterfield, Russell J","Rao, Vamshi K","Smith, Edward C","Proud, Crystal M","Connolly, Anne M","Ciafaloni, Emma","32329920"],"abstract":["The corona virus disease 2019 (COVID-19) pandemic has resulted in the reorganization of healthcare settings affecting clinical care delivery to patients with Duchenne and Becker muscular dystrophy (DBMD) as well as other inherited muscular dystrophies. The magnitude of the impact of this public health emergency on the care of patients with DBMD is unclear as they are suspected of having an increased risk for severe manifestations of COVID-19. In this paper, the authors discuss their consensus recommendations pertaining to care of these patients during the pandemic. We address issues surrounding corticosteroid and exon skipping treatments, cardiac medications, hydroxychloroquine use, emergency/respiratory care, rehabilitation management, and the conduct of clinical trials. We highlight the importance of collaborative treatment decisions between the patient, family, and health care provider, considering any geographic or institution-specific policies and precautions for COVID-19. We advocate for continuing multidisciplinary care for these patients using telehealth. This article is protected by copyright. All rights reserved."],"journal":"Muscle Nerve","authors":["Veerapandiyan, Aravindhan","Wagner, Kathryn R","Apkon, Susan","McDonald, Craig M","Mathews, Katherine D","Parsons, Julie A","Wong, Brenda L","Eichinger, Katy","Shieh, Perry B","Butterfield, Russell J","Rao, Vamshi K","Smith, Edward C","Proud, Crystal M","Connolly, Anne M","Ciafaloni, Emma"],"date":"2020-04-25T11:00:00Z","year":2020,"_id":"32329920","week":"202017|Apr 20 - Apr 26","doi":"10.1002/mus.26902","keywords":["bmd","covid19","dmd","consensus","muscular dystrophy","recommendations"],"source":"PubMed","topics":["Prevention"],"weight":1,"e_drugs":["Hydroxychloroquine"],"_version_":1664996914918064129,"score":8.518259,"similar":[{"pmid":32329921,"title":"Spinal muscular atrophy care in the COVID-19 pandemic era.","text":["Spinal muscular atrophy care in the COVID-19 pandemic era.","The Corona Virus Disease 2019 (COVID-19) pandemic has resulted in reorganization of healthcare settings affecting the delivery of clinical care to patients with spinal muscular atrophy (SMA). There is a concern that patients with SMA may be at increased risk of manifesting severe symptoms of COVID-19. Currently approved therapies for SMA improve survival and motor function, however, their delivery requires an increased exposure to the health system and a dedicated healthcare team. In this paper, we discuss consensus recommendations pertaining to care of SMA patients during the pandemic. We highlight that SMA treatments should not be perceived as elective. Decisions regarding the delay of treatments should be made with consideration of the potential risks of COVID-19 exposure and the risk of that delay. We emphasize the importance of collaborative treatment decisions between the patient, family, and health care provider, considering any geographic or institution-specific policies and precautions for COVID-19. This article is protected by copyright. All rights reserved.","Muscle Nerve","Veerapandiyan, Aravindhan","Connolly, Anne M","Finkel, Richard S","Arya, Kapil","Mathews, Katherine D","Smith, Edward C","Castro, Diana","Butterfield, Russell J","Parsons, Julie A","Servais, Laurent","Kuntz, Nancy","Rao, Vamshi K","Brandsema, John F","Mercuri, Eugenio","Ciafaloni, Emma","32329921"],"abstract":["The Corona Virus Disease 2019 (COVID-19) pandemic has resulted in reorganization of healthcare settings affecting the delivery of clinical care to patients with spinal muscular atrophy (SMA). There is a concern that patients with SMA may be at increased risk of manifesting severe symptoms of COVID-19. Currently approved therapies for SMA improve survival and motor function, however, their delivery requires an increased exposure to the health system and a dedicated healthcare team. In this paper, we discuss consensus recommendations pertaining to care of SMA patients during the pandemic. We highlight that SMA treatments should not be perceived as elective. Decisions regarding the delay of treatments should be made with consideration of the potential risks of COVID-19 exposure and the risk of that delay. We emphasize the importance of collaborative treatment decisions between the patient, family, and health care provider, considering any geographic or institution-specific policies and precautions for COVID-19. This article is protected by copyright. All rights reserved."],"journal":"Muscle Nerve","authors":["Veerapandiyan, Aravindhan","Connolly, Anne M","Finkel, Richard S","Arya, Kapil","Mathews, Katherine D","Smith, Edward C","Castro, Diana","Butterfield, Russell J","Parsons, Julie A","Servais, Laurent","Kuntz, Nancy","Rao, Vamshi K","Brandsema, John F","Mercuri, Eugenio","Ciafaloni, Emma"],"date":"2020-04-25T11:00:00Z","year":2020,"_id":"32329921","week":"202017|Apr 20 - Apr 26","doi":"10.1002/mus.26903","source":"PubMed","topics":["Prevention"],"weight":1,"_version_":1664996914936938496,"score":646.5987},{"pmid":32329926,"title":"Tracheostomy guidelines developed at a large academic medical center during the COVID-19 pandemic.","text":["Tracheostomy guidelines developed at a large academic medical center during the COVID-19 pandemic.","BACKGROUND: During the SARS-CoV-2 pandemic, tracheostomy may be required for COVID-19 patients requiring long term ventilation in addition to other conditions such as airway compromise from head and neck cancer. As an aerosol generating procedure, tracheostomy increases healthcare worker exposure to COVID-19 infection. Performing surgical tracheostomy and tracheostomy care requires a strategy that mitigates these risks and maintains the quality of patient care. METHODS: A multidisciplinary review of institutional tracheostomy guidelines and clinical pathways. Modifications to support clinical-decision making in the context of COVID-19 were derived by consensus and available evidence. RESULTS: Modified guidelines for all phases of tracheostomy care at an academic tertiary care center in the setting of COVID-19 are presented. DISCUSSION: During the various phases of the COVID-19 pandemic, clinicians must carefully consider the indications, procedural precautions, and post-operative care for tracheostomies. We present guidelines to mitigate risk to healthcare workers while preserving the quality of care. This article is protected by copyright. All rights reserved.","Head Neck","David, Abel P","Russell, Marika D","El-Sayed, Ivan H","Russell, Matthew S","32329926"],"abstract":["BACKGROUND: During the SARS-CoV-2 pandemic, tracheostomy may be required for COVID-19 patients requiring long term ventilation in addition to other conditions such as airway compromise from head and neck cancer. As an aerosol generating procedure, tracheostomy increases healthcare worker exposure to COVID-19 infection. Performing surgical tracheostomy and tracheostomy care requires a strategy that mitigates these risks and maintains the quality of patient care. METHODS: A multidisciplinary review of institutional tracheostomy guidelines and clinical pathways. Modifications to support clinical-decision making in the context of COVID-19 were derived by consensus and available evidence. RESULTS: Modified guidelines for all phases of tracheostomy care at an academic tertiary care center in the setting of COVID-19 are presented. DISCUSSION: During the various phases of the COVID-19 pandemic, clinicians must carefully consider the indications, procedural precautions, and post-operative care for tracheostomies. We present guidelines to mitigate risk to healthcare workers while preserving the quality of care. This article is protected by copyright. All rights reserved."],"journal":"Head Neck","authors":["David, Abel P","Russell, Marika D","El-Sayed, Ivan H","Russell, Matthew S"],"date":"2020-04-25T11:00:00Z","year":2020,"_id":"32329926","week":"202017|Apr 20 - Apr 26","doi":"10.1002/hed.26191","keywords":["covid-19","coronavirus","personal protective equipment (ppe)","tracheostomy","tracheotomy"],"source":"PubMed","topics":["Prevention"],"weight":1,"_version_":1664996914927501313,"score":248.39627},{"pmid":32317433,"title":"All India Ophthalmological Society - Indian Journal of Ophthalmology consensus statement on preferred practices during the COVID-19 pandemic.","text":["All India Ophthalmological Society - Indian Journal of Ophthalmology consensus statement on preferred practices during the COVID-19 pandemic.","The COVID-19 pandemic has taken tragic proportions and has disrupted lives globally. In the wake of governmental lockdowns, ophthalmologists need practical and actionable guidelines based on advisories from national health departments on how to conduct their duties during nationwide lockdowns and after these are lifted. In this paper, we present a preferred practice pattern (PPP) based on consensus discussions between leading ophthalmologists and health care professionals in India including representatives from major governmental and private institutions as well as the All India Ophthalmological Society leadership. In this document, the expert panel clearly defines the range of activities for Indian ophthalmologists during the ongoing lockdown phase and precautions to be taken once the lockdown is lifted. Guidelines for triage, governmental guidelines for use of personal protective equipment from ophthalmologists' point of view, precautions to be taken in the OPD and operating room as well as care of various ophthalmic equipment have been described in detail. These guidelines will be applicable to all practice settings including tertiary institutions, corporate and group practices and individual eye clinics and should help Indian ophthalmologists in performing their professional responsibilities without being foci of disease transmission.","Indian J Ophthalmol","Sengupta, Sabyasachi","Honavar, Santosh G","Sachdev, Mahipal S","Sharma, Namrata","Kumar, Atul","Ram, Jagat","Shetty, Rohit","Rao, Girish S","Ramasamy, Kim","Khanna, Rohit","Jain, Elesh","Bhattacharjee, Kasturi","Agarwal, Ashvin","Natarajan, S","Lahane, Tatyarao P","32317433"],"abstract":["The COVID-19 pandemic has taken tragic proportions and has disrupted lives globally. In the wake of governmental lockdowns, ophthalmologists need practical and actionable guidelines based on advisories from national health departments on how to conduct their duties during nationwide lockdowns and after these are lifted. In this paper, we present a preferred practice pattern (PPP) based on consensus discussions between leading ophthalmologists and health care professionals in India including representatives from major governmental and private institutions as well as the All India Ophthalmological Society leadership. In this document, the expert panel clearly defines the range of activities for Indian ophthalmologists during the ongoing lockdown phase and precautions to be taken once the lockdown is lifted. Guidelines for triage, governmental guidelines for use of personal protective equipment from ophthalmologists' point of view, precautions to be taken in the OPD and operating room as well as care of various ophthalmic equipment have been described in detail. These guidelines will be applicable to all practice settings including tertiary institutions, corporate and group practices and individual eye clinics and should help Indian ophthalmologists in performing their professional responsibilities without being foci of disease transmission."],"journal":"Indian J Ophthalmol","authors":["Sengupta, Sabyasachi","Honavar, Santosh G","Sachdev, Mahipal S","Sharma, Namrata","Kumar, Atul","Ram, Jagat","Shetty, Rohit","Rao, Girish S","Ramasamy, Kim","Khanna, Rohit","Jain, Elesh","Bhattacharjee, Kasturi","Agarwal, Ashvin","Natarajan, S","Lahane, Tatyarao P"],"date":"2020-04-23T11:00:00Z","year":2020,"_id":"32317433","week":"202017|Apr 20 - Apr 26","doi":"10.4103/ijo.IJO_871_20","keywords":["covid-19","consensus","guidelines","lockdown","ophthalmology","pandemic","precautions","preferred practice"],"source":"PubMed","topics":["Prevention"],"weight":1,"locations":["India","Indian","Indian"],"countries":["India"],"countries_codes":["IND|India"],"_version_":1664815087879192576,"score":230.69786},{"pmid":32298029,"title":"How to Guarantee the Best of Care to Patients with Cancer During the COVID-19 Epidemic: The Italian Experience.","text":["How to Guarantee the Best of Care to Patients with Cancer During the COVID-19 Epidemic: The Italian Experience.","Italy and the rest of the world are experiencing an outbreak of a novel beta-coronavirus known as severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). In this context, in Italy, we reorganized the National Health System and prioritized the clinical cancer care scenario, balancing risk of SARS-CoV-2 transmission versus the magnitude of clinical benefit deriving from a specific therapeutic approach. As initial actions, we recommended that routine screening be suspended and that patients with early and advanced cancer be treated as outpatients as much as possible and at the nearest medical center. Patients who need to be hospitalized for cancer treatment were protected from potential SARS-CoV-2 infection by creating a dedicated diagnostic and therapeutic internal pathway for cancer treatment. We implemented reorganization of the hospital networks, based on a hub-and-spoke design. Stronger personal protection was made available for patients with cancer. Because of the extreme burden created by COVID-19, antitumor treatment was initiated only after considering patient performance status, comorbidities, biology of disease, and the likely impact of treatment on outcome. Treatment strategies were discussed in the context of a multidisciplinary tumor board. Treatment decision making balanced risk and benefits of treatment in the context of the specific pandemic level, on a case-by-case basis.","Oncologist","Curigliano, Giuseppe","32298029"],"abstract":["Italy and the rest of the world are experiencing an outbreak of a novel beta-coronavirus known as severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). In this context, in Italy, we reorganized the National Health System and prioritized the clinical cancer care scenario, balancing risk of SARS-CoV-2 transmission versus the magnitude of clinical benefit deriving from a specific therapeutic approach. As initial actions, we recommended that routine screening be suspended and that patients with early and advanced cancer be treated as outpatients as much as possible and at the nearest medical center. Patients who need to be hospitalized for cancer treatment were protected from potential SARS-CoV-2 infection by creating a dedicated diagnostic and therapeutic internal pathway for cancer treatment. We implemented reorganization of the hospital networks, based on a hub-and-spoke design. Stronger personal protection was made available for patients with cancer. Because of the extreme burden created by COVID-19, antitumor treatment was initiated only after considering patient performance status, comorbidities, biology of disease, and the likely impact of treatment on outcome. Treatment strategies were discussed in the context of a multidisciplinary tumor board. Treatment decision making balanced risk and benefits of treatment in the context of the specific pandemic level, on a case-by-case basis."],"journal":"Oncologist","authors":["Curigliano, Giuseppe"],"date":"2020-04-17T11:00:00Z","year":2020,"_id":"32298029","week":"202016|Apr 13 - Apr 19","doi":"10.1634/theoncologist.2020-0267","source":"PubMed","topics":["Treatment"],"weight":1,"locations":["Italy","Italy","Italian"],"countries":["Italy"],"countries_codes":["ITA|Italy"],"_version_":1664641388275302400,"score":219.01987},{"pmid":32259288,"title":"Caring for patients with pain during the COVID-19 pandemic: Consensus recommendations from an international expert panel.","text":["Caring for patients with pain during the COVID-19 pandemic: Consensus recommendations from an international expert panel.","Chronic pain causes significant suffering, limitation of daily activities and reduced quality of life. Infection from COVID-19 is responsible for an ongoing pandemic that causes severe acute respiratory syndrome, leading to systemic complications and death. Led by the World Health Organization, healthcare systems across the world are engaged in limiting the spread of infection. As a result all elective surgeries, procedures, and patient visits, including pain management services, have been postponed or cancelled. This has impacted the care of chronic pain patients. Most are elderly with multiple comorbidities, which puts them at risk of COVID-19 infection. Important considerations that need to be recognised during this pandemic for chronic pain patients include: ensuring continuity of care and pain medications, especially opioids; use of telemedicine; maintaining biopsychosocial management; use of anti-inflammatory drugs; use of steroids; and prioritising necessary procedural visits. There are no guidelines to inform physicians and healthcare providers engaged in caring for patients with pain during this period of crisis. We assembled an expert panel of pain physicians, psychologists and researchers from North America and Europe to formulate recommendations to guide practice. As the COVID-19 situation continues to evolve rapidly, these recommendations are based on the best available evidence and expert opinion at this present time and may need adapting to local workplace policies.","Anaesthesia","Shanthanna, H","Strand, N H","Provenzano, D A","Lobo, C A","Eldabe, S","Bhatia, A","Wegener, J","Curtis, K","Cohen, S P","Narouze, S","32259288"],"abstract":["Chronic pain causes significant suffering, limitation of daily activities and reduced quality of life. Infection from COVID-19 is responsible for an ongoing pandemic that causes severe acute respiratory syndrome, leading to systemic complications and death. Led by the World Health Organization, healthcare systems across the world are engaged in limiting the spread of infection. As a result all elective surgeries, procedures, and patient visits, including pain management services, have been postponed or cancelled. This has impacted the care of chronic pain patients. Most are elderly with multiple comorbidities, which puts them at risk of COVID-19 infection. Important considerations that need to be recognised during this pandemic for chronic pain patients include: ensuring continuity of care and pain medications, especially opioids; use of telemedicine; maintaining biopsychosocial management; use of anti-inflammatory drugs; use of steroids; and prioritising necessary procedural visits. There are no guidelines to inform physicians and healthcare providers engaged in caring for patients with pain during this period of crisis. We assembled an expert panel of pain physicians, psychologists and researchers from North America and Europe to formulate recommendations to guide practice. As the COVID-19 situation continues to evolve rapidly, these recommendations are based on the best available evidence and expert opinion at this present time and may need adapting to local workplace policies."],"journal":"Anaesthesia","authors":["Shanthanna, H","Strand, N H","Provenzano, D A","Lobo, C A","Eldabe, S","Bhatia, A","Wegener, J","Curtis, K","Cohen, S P","Narouze, S"],"date":"2020-04-08T11:00:00Z","year":2020,"_id":"32259288","week":"202015|Apr 06 - Apr 12","doi":"10.1111/anae.15076","keywords":["covid-19","chronic pain","opioids","recommendations","steroids"],"source":"PubMed","topics":["Prevention"],"weight":1,"e_drugs":["Steroids"],"_version_":1664640769860829185,"score":206.69928}]}